Innoviva (INVA) Total Current Liabilities (2010 - 2026)
Innoviva posted quarterly Total Current Liabilities of $36.6 million for Q1 2026, down 84.43% year-on-year from $234.7 million in Q1 2025, and down 26.44% on a QoQ basis from $49.7 million in Q4 2025.
Innoviva (INVA) has 17 years of Total Current Liabilities data on file, last reported at $36.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 84.43% year-over-year to $36.6 million; the trailing twelve-month figure through Mar 2026 stood at $36.6 million (down 84.43% YoY), and the FY2025 full-year result was $49.7 million, down 78.95% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $36.6 million, down from $49.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $246.6 million in Q2 2025 and bottomed at $7.0 million in Q3 2022.
- The 5-year median for Total Current Liabilities is $49.7 million (2025), against an average of $96.1 million.
- The widest annual swing landed in 2022, when Total Current Liabilities jumped 2771.37%; it then slumped 84.43% in 2026.
- A 5-year view of Total Current Liabilities shows it stood at $135.0 million in 2022, then plunged by 71.75% to $38.1 million in 2023, then jumped by 519.09% to $236.1 million in 2024, then tumbled by 78.95% to $49.7 million in 2025, then slipped by 26.44% to $36.6 million in 2026.
- The last three Total Current Liabilities figures came in at $36.6 million (Q1 2026), $49.7 million (Q4 2025), and $140.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 36.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.56 Mn |
| Dec 31, 2025 | 49.70 Mn |
| Sep 30, 2025 | 139.95 Mn |
| Jun 30, 2025 | 246.56 Mn |
| Mar 31, 2025 | 234.75 Mn |
| Dec 31, 2024 | 236.08 Mn |
| Sep 30, 2024 | 118.20 Mn |
| Jun 30, 2024 | 28.21 Mn |
| Mar 31, 2024 | 29.88 Mn |
| Dec 31, 2023 | 38.13 Mn |
| Sep 30, 2023 | 21.88 Mn |
| Jun 30, 2023 | 39.40 Mn |
| Mar 31, 2023 | 38.14 Mn |
| Dec 31, 2022 | 134.97 Mn |
| Sep 30, 2022 | 7.00 Mn |
| Jun 30, 2022 | 125.91 Mn |
| Mar 31, 2022 | 109.23 Mn |
| Dec 31, 2021 | 5.81 Mn |
| Sep 30, 2021 | 5.25 Mn |
| Jun 30, 2021 | 5.37 Mn |
| Mar 31, 2021 | 3.80 Mn |
| Dec 31, 2020 | 6.11 Mn |
| Sep 30, 2020 | 7.07 Mn |
| Jun 30, 2020 | 5.41 Mn |
| Mar 31, 2020 | 2.80 Mn |
| Dec 31, 2019 | 5.37 Mn |
| Sep 30, 2019 | 3.33 Mn |
| Jun 30, 2019 | 7.48 Mn |
| Mar 31, 2019 | 3.81 Mn |
| Dec 31, 2018 | 5.70 Mn |
| Sep 30, 2018 | 4.30 Mn |
| Jun 30, 2018 | 6.78 Mn |
| Mar 31, 2018 | 4.07 Mn |
| Dec 31, 2017 | 34.74 Mn |
| Sep 30, 2017 | 32.88 Mn |
| Jun 30, 2017 | 27.11 Mn |
| Mar 31, 2017 | 20.47 Mn |
| Dec 31, 2016 | 20.05 Mn |
| Sep 30, 2016 | 14.92 Mn |
| Jun 30, 2016 | 14.63 Mn |
| Mar 31, 2016 | 10.62 Mn |
| Dec 31, 2015 | 13.49 Mn |
| Sep 30, 2015 | 11.28 Mn |
| Jun 30, 2015 | 12.21 Mn |
| Mar 31, 2015 | 10.98 Mn |
| Dec 31, 2014 | 13.76 Mn |
| Sep 30, 2014 | 36.10 Mn |
| Jun 30, 2014 | 49.99 Mn |
| Mar 31, 2014 | 44.14 Mn |
| Dec 31, 2013 | 84.40 Mn |
| Sep 30, 2013 | 38.66 Mn |
| Jun 30, 2013 | 38.65 Mn |
| Mar 31, 2013 | 29.46 Mn |
| Dec 31, 2012 | 29.97 Mn |
| Sep 30, 2012 | 27.09 Mn |
| Jun 30, 2012 | 25.78 Mn |
| Mar 31, 2012 | 25.58 Mn |
| Dec 31, 2011 | 45.50 Mn |
| Sep 30, 2011 | 39.81 Mn |
| Jun 30, 2011 | 35.19 Mn |
| Dec 31, 2010 | 40.05 Mn |